PubMed indexes 222 BPC-157 papers and not one is about hair. The claim traces to a 2001 experiment that burned mice, and the trial clinics cite for scalp injections cannot be found in any database.
BPC-157 is going viral for hair growth. The claim arrived without any data attached, so we went looking for the data.
The short answer: There is no evidence that BPC-157 grows hair, because there is no study. PubMed indexes 222 BPC-157 papers as of July 2026, and not one is about hair, alopecia, hair follicles, or scalp. Europe PMC full text, Crossref, and OpenAlex return nothing either, including preprints and conference abstracts. No human trial, no animal study, and no lab study has ever tested BPC-157 on hair in any model. BPC-157 for hair is untested, not disproven, and that is a very long way from what is being sold.
The entire claim is a mechanistic story extrapolated from burn-wound experiments in mice, and some of the "clinical evidence" circulating online points to a study that cannot be found in any database.
For the structured claim-by-claim breakdown with evidence grades, see our BPC-157 treatment science page. This article is the story of where the hair claim came from.
BPC-157, or body protection compound 157, is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV. It is described in the literature as a fragment derived from a protein found in human gastric juice, though that parent protein has never been published in a form anyone else can reproduce.
It is not an approved drug. Per the FDA's own briefing document from May 2026, "There is no approved product containing BPC-157-related BDSs in any country at this time, nor is BPC-157 (free base) or BPC-157 acetate found in the European, Japanese, or the International Pharmacopeias" (FDA 2026). The World Anti-Doping Agency banned it by name, at all times, in and out of competition, effective 1 January 2022 (WADA 2022).
It is best known in fitness and biohacking circles as a healing peptide for tendon, ligament, and gut injuries. Hair is a recent addition to its reputation, and it arrived without any data attached. We covered where it sits among the rest of the category in our guide to peptides for hair growth.
No. This is worth being precise about, because the answer is unusually clean.
Searching PubMed for ("BPC 157" OR "BPC-157" OR "body protection compound 157") returns 222 papers as of July 2026. Adding AND hair returns zero. So does AND alopecia. So does AND "hair follicle", AND "dermal papilla", AND scalp, and AND keratinocyte.
PubMed searches titles and abstracts, so we checked databases that search full text and grey literature too. Europe PMC, which indexes full text plus preprints and conference abstracts, returns no BPC-157 hair studies. Neither does Crossref. Neither does OpenAlex.
The clinical trial registry tells the same story. Only two BPC-157 trials have ever been registered anywhere in the world: NCT02637284, a Phase 1 pharmacokinetic study in healthy volunteers that went silent in December 2015 without posting results, and NCT07437547, a Phase 2 trial for acute hamstring strain that began recruiting in February 2026. Neither has anything to do with hair.
This is the interesting part. The trail leads to a single sentence in a burn study.
In 2001, researchers induced deep partial-thickness burns on the backs of mice and applied BPC-157 cream to the wounds. Among the histology findings, they reported: "An increased number of preserved follicles were observed" (Mikus 2001).
That sentence has been passed around as evidence that BPC-157 helps hair follicles. It does not mean what it sounds like.
In that study, follicles were a measure of how deep the burn went. The paper's own necrosis grading scale is defined by follicle depth: "Grade 2: necrosis up to the deepest layer of hair follicles. Grade 3: necrosis exceeding the deepest layer of hair follicles" (Mikus 2001). The researchers counted preserved follicles "in three microscopic fields (mag. 25x) in the middle of the burned area and examining the deepest layer of hair follicles."
In other words, they were measuring how much tissue survived a fire. Not whether hair grew. And the mice had their backs shaved 24 hours before the experiment, which is standard for a burn model and further removes it from anything resembling a hair-growth readout.
A wound-healing agent limiting burn damage to the deep dermis is a reasonable finding. It is not a hair-growth finding, and there is no version of it that becomes one.
This is the part worth reading closely if you are considering paying for scalp injections.
Several clinics and peptide vendors selling BPC-157 for hair cite a specific trial. The claim, quoted verbatim from one dermatology practice's page, reads: "In a clinical study of 30 patients with androgenetic alopecia (male or female pattern baldness), stem cell peptide BPC-157 hair loss treatment injections were found to improve hair density and thickness. After six months of treatment, patients showed a significant increase in the number of hairs per square centimeter and an increase in hair thickness."
We could not find that study. It is not in PubMed. It is not in Europe PMC full text, which searches the body of papers rather than just abstracts. It is not in the clinical trial registry, which as noted contains exactly two BPC-157 trials, neither about hair. The claim appears on at least four separate sites, paraphrased rather than copied, all tracing back to the same uncited assertion.
One of those sites does attach a citation to it: PMID 34486824.
Look it up. That paper is Ohn et al. (2021), "Discovery of a transdermally deliverable pentapeptide for activating AdipoR1 to promote hair growth," published in EMBO Molecular Medicine. It is about a 5-amino-acid peptide called GLYYF, or P5, which activates adiponectin receptor 1. It is a genuinely interesting paper. It has nothing to do with BPC-157, which it never mentions. And it has zero human patients: the work was done in ex vivo hair follicles and in mice.
A different molecule's mouse study, cited as a 30-person human trial.
The same page's other three citations are all GHK-Cu papers, covering pulmonary fibrosis and skin ageing. Not one BPC-157 paper appears on it.
We want to be careful about what this does and does not prove. It does not prove that no clinic anywhere has ever collected unpublished data. It does prove that the citation offered in public as evidence does not say what it is claimed to say, and that anyone can verify this in about thirty seconds.
This is the strongest version of the pro-BPC-157 case, and it deserves a fair hearing rather than a dismissal.
The argument goes: BPC-157 is angiogenic, meaning it promotes new blood vessel growth. Hair follicles in the growth phase are among the most vascularised structures in skin. Therefore more blood vessels should mean more hair.
Two things about that argument are true.
First, BPC-157 really does appear to be angiogenic, and this has been replicated outside the Croatian group that discovered it. Huang et al. (2015), working at the Fourth Military Medical University in Xi'an, found that BPC-157 "upregulated the expression of VEGF-a and accelerated vascular tube formation in vitro," alongside accelerated wound closure in an alkali-burn rat model.
Second, vascular supply genuinely does matter for hair. In a landmark study, Yano et al. (2001) showed that "transgenic overexpression of VEGF in outer root sheath keratinocytes of hair follicles strongly induced perifollicular vascularization, resulting in accelerated hair regrowth after depilation and in increased size of hair follicles and hair shafts."
So the reasoning is not stupid. It is just not evidence, and it does not survive contact with three problems.
Vendors routinely write that BPC-157 upregulates VEGF, the growth factor. The paper most often cited for this found something different. Hsieh et al. (2017) reported that "in vitro study using human vascular endothelial cells further confirmed the increased mRNA and protein expressions of VEGFR2 but not VEGF-A by BPC 157."
VEGFR2 is the receptor. VEGF-A is the ligand. Upregulating a receptor is not the same as producing more growth factor, and the distinction matters for any story about driving new follicular vasculature.
It is also worth noting what Hsieh et al. actually studied: chick chorioallantoic membrane, rat hind limb ischaemia, and human umbilical vein endothelial cells. No hair. No skin. No scalp.
To be fair to the mechanism, Huang et al. (2015) did find VEGF-A upregulation, so the honest statement is not "BPC-157 never touches VEGF." It is that every model in which VEGF-A rises is an injury model. Burns, ischaemia, ulcers, transections. A balding scalp is not a wound.
When the Zagreb group defended BPC-157 against concerns that a pro-angiogenic compound might carry tumour risk, they argued that it does not indiscriminately grow blood vessels. In their words, BPC-157 "resolved cornea transparency maintenance, cornea healing 'angiogenic privilege' (vs. angiogenesis/neovascularization/tumorogenesis), does not produce corneal neovascularization, but rather opposes it" and "controls angiogenesis" (Sikiric 2025). An earlier review from the same group called it "the most potent angiomodulatory agent... leading to optimization of the vascular response" (Seiwerth 2014).
Angiomodulatory, not angiogenic. Their safety argument is that BPC-157 does not simply grow vessels wherever it lands, but instead nudges tissue toward whatever its correct vascular state is, actively opposing neovascularisation in the cornea.
The hair argument requires the opposite: that it will grow new vessels in a scalp that is not injured and not ischaemic. Both cannot be true. This point comes from a motivated source defending its own compound, which is precisely what makes it useful. It is a hostile witness.
This is the one that ends the argument, and we have made it at length before in does minoxidil work by increasing blood flow?. The short version follows.
It is true that balding scalp has measurably lower blood flow. Klemp et al. (1989) found subcutaneous perfusion 2.6 times lower in early male pattern baldness, 13.7 versus 35.7 ml/100 g/min, p<0.001. Nailfold capillaroscopy abnormalities are also more common in androgenetic alopecia (Cao 2022). Anyone arguing the blood-flow case will reach for these, and they are real findings.
But the direction of causation runs the other way. A miniaturised follicle is a smaller, less metabolically demanding structure, so it recruits and needs less blood. Perfusion tracks follicle size rather than driving it. Klemp himself only ventured that reduced flow "might be a significant event" in pathogenesis. His own data also show that normal scalp perfusion runs roughly ten times higher than other body regions, so balding scalp is not ischaemic tissue in any absolute sense.
The decisive evidence is donor dominance, the principle modern hair transplantation is built on. Take a follicle from the back of the head and move it into the bald patch, and it grows there for life. Take a balding-prone follicle and move it anywhere you like, and it still balds. Same blood supply, opposite outcomes. As a recent state-of-the-art review puts it, hair transplantation is "based on the principle of donor dominance, where transplanted hair retains its genetic characteristics in new locations" (Queen 2025). The principle traces to Orentreich (1959), the paper that founded the field.
If the bald scalp were a poor-perfusion environment, transplanted follicles placed into it would fail. They do not. The instruction is inside the follicle, not the plumbing. You do not fix an androgen-driven problem with circulation.
Set aside whether the mechanism makes sense for a moment. There is a more basic problem, and it comes before the biology: getting the molecule to the target at all.
BPC-157 is a pentadecapeptide. Fifteen amino acids, molecular formula C62H98N16O22, molecular weight 1,419 daltons (PubChem CID 9941957). That figure is not in dispute. It appears verbatim in the literature, including in a paper Sikirić himself co-authored: "BPC157 has the following amino acid sequence and molecular weight (MW): GlyGluProProProGlyLysProAlaAspAspAlaGlyLeuVal, MW = 1419" (Tohyama 2004).
Now compare that to what skin will let through. The widely cited 500 Dalton rule holds that "the molecular weight (MW) of a compound must be under 500 Dalton to allow skin absorption. Larger molecules cannot pass the corneal layer" (Bos 2000). For scale, topical minoxidil is 209 daltons and finasteride is 372. Both sit comfortably under the ceiling. BPC-157 is nearly three times over it, and it is hydrophilic, with no known transporter and no identified molecular target (FDA 2026).
So a BPC-157 serum sprayed or rubbed on the scalp in an ordinary vehicle is not plausibly reaching the dermal papilla. That is a delivery problem before it is ever an efficacy problem.
Two honest caveats. The 500 Dalton rule is a rule of thumb argued from contact allergens and topical drug precedent, not a hard physical cutoff, and a serious delivery system such as liposomal encapsulation or microneedling changes the calculation. And nobody has actually measured BPC-157 penetration through scalp skin, so this is a well-supported inference from molecular weight rather than a measured finding.
Injecting it into the scalp sidesteps the size problem entirely, which is presumably why clinics sell injections rather than serums. But that route runs straight back into the previous section: the follicle was never short of blood in the first place. And BPC-157's plasma half-life is under 30 minutes (Mateescu 2026), which leaves a narrow window for anything to happen.
Taken together, every route people actually use fails for its own reason. Topical is too large to get in. Injection gets in but addresses a problem androgenetic alopecia does not have. And oral, as the next section covers, has never been studied in humans at all.
Set hair aside for a moment. Even on its home turf, the literature has structural problems worth knowing about.
Of the 222 BPC-157 papers on PubMed, 174 (78.4 percent) are authored by a single researcher, Predrag Sikirić at the University of Zagreb. Roughly 87 percent of his entire published career is this one molecule. When you filter out reviews, editorials, analytical and doping-detection papers, work by the commercial developer, and non-studies, the number of genuinely independent primary experimental studies is about 15 of 222, roughly 6.8 percent, from seven groups. That figure is an upper bound, since older PubMed records often list only the first author's affiliation.
Across his BPC-157 papers, self-citation runs at about 43.7 percent of all references, against a typical biomedical baseline nearer 10 to 20 percent.
Then there is the dose pattern. Around 80 percent of the Zagreb papers that report a per-kilogram dose use one of the same two: 10 µg/kg or 10 ng/kg. Nearly 40 percent use both in the same study and report them as equally effective. That is a thousand-fold difference producing the same result, across models as unrelated as rat glaucoma, myocardial infarction, and cysteamine colitis. There is no ED50 anywhere in the corpus and no dose-response curve. Independent labs do not use that dose pair at all.
A dose-response relationship is the most basic evidence that a compound is doing what you think it is doing. A compound that works identically at a thousandfold dilution in every organ in the body is not a pharmacological discovery. It is a signal that something in the measurement is not tracking dose.
Also worth noting: no receptor or molecular target for BPC-157 has ever been identified. The FDA states plainly that "the molecular targets for BPC-157-related substances have not been identified" (FDA 2026). Most peptides need a receptor to do anything.
None of this proves BPC-157 does nothing. A single productive lab is not automatically wrong, and the Taiwanese replications of the angiogenesis work are real. But it does mean the evidence base is far thinner and far more concentrated than the confidence of the marketing suggests.
Very little, and none of it is about hair.
The FDA's May 2026 briefing document contains the single most clarifying sentence in this whole story: "We found no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal ROA" (FDA 2026).
Read that again. Oral, subcutaneous, nasal, transdermal. Those are every route people actually use. All of them have zero human data.
The human exposure data that does exist comes from rectal enema studies, in which BPC-157 was not detected in plasma at all, plus a small number of uncontrolled case series by a single author, with between 2 and 17 participants each, published in a complementary medicine journal. The only randomised controlled trial ever conducted, in ulcerative colitis, exists solely as a conference abstract, and its result was null: the between-group difference was 1.6 points with a 95 percent confidence interval of −4.84 to 1.62, which crosses zero.
An independent 2026 review summarised the state of play: BPC-157's "pharmaceutical development remains rudimentary, with no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial" (Mateescu 2026). Its plasma half-life is under 30 minutes.
We want to be clear about the limits of our own argument.
We do not know that BPC-157 does nothing for hair. Nobody does, because nobody has looked. It is possible that a properly designed study would find something. The peptide is genuinely angiogenic, angiogenesis genuinely matters for the hair cycle, and those two facts make it a reasonable thing to test.
We also cannot rule out that some clinic somewhere has collected unpublished before-and-after data. What we can say is that no such data has been published, and that the citation offered publicly as proof points to a study of a different molecule with no human subjects.
The question could be settled relatively cheaply. Human hair follicle organ culture, testing BPC-157 at 1 to 100 nM on microdissected anagen follicles, with hair shaft elongation and Ki-67 proliferation as endpoints, would produce a real answer in about six days. Until somebody runs it, every claim about BPC-157 and hair is extrapolation.
BPC-157 for hair is not disproven. It is untested. Those are different things, and the difference is the entire point.
Being untested would be a fine reason for curiosity. It is not a reason to inject an unapproved peptide into your scalp on the strength of a burn study in mice and a citation that points to the wrong molecule.
You are being sold a mechanism, not a medicine.
No. Only two BPC-157 trials have ever been registered anywhere: a Phase 1 pharmacokinetic study that went silent in 2015 without posting results, and a 2026 hamstring-strain trial. Neither concerns hair. The widely cited 30-patient androgenetic alopecia study appears in no database, and the PMID attached to it describes a different peptide with no human participants.
A 2001 mouse burn study reported 'an increased number of preserved follicles' after BPC-157 cream. In that paper, follicle counts measured how deep the burn damage went, not hair growth. BPC-157 is also angiogenic, so the leap to 'more blood flow means more hair' feels intuitive. Androgenetic alopecia is not caused by poor blood supply.
Almost certainly not in an ordinary vehicle. BPC-157 weighs 1,419 daltons, and the 500 Dalton rule holds that larger molecules cannot cross the stratum corneum (Bos 2000). Topical minoxidil is 209 daltons. This is an inference from molecular weight rather than a measurement, and a delivery system such as liposomes or microneedling could change it.
No. BPC-157 is not approved for any indication in any country and appears in no major pharmacopeia. The World Anti-Doping Agency has banned it by name since 1 January 2022. The FDA listed it as a bulk substance presenting significant safety risks in 2023, and its own briefing document recommends against adding it to the 503A bulks list.
There is no controlled data either way. Scattered user reports describe both thicker body hair and increased scalp shedding, but these are anecdotes without controls, dose verification, or product testing. Since no study has measured hair on BPC-157 at all, nothing can be concluded about hair growth or hair loss from the literature.
Androgenetic alopecia is driven by DHT signalling at genetically susceptible follicles, so the treatments with real human evidence target that pathway. Topical minoxidil is FDA-approved for pattern hair loss, as is oral finasteride for men. Oral minoxidil, dutasteride, topical finasteride and spironolactone are used off-label and are decisions to make with a clinician.
This article is for educational purposes only and is not medical advice. It does not recommend or endorse the use of BPC-157, which is not approved by the FDA for any indication in any country and is prohibited by the World Anti-Doping Agency. Several treatments referenced here, including oral minoxidil, dutasteride, topical finasteride, and spironolactone, are used off-label for androgenetic alopecia in the United States; topical minoxidil and oral finasteride are FDA-approved for pattern hair loss. Any treatment decision should be made with a qualified clinician who knows your history. Anagen does not sell BPC-157.